Generics US specialty pharmaceutical company Sagent Pharmaceuticals (Nasdaq: SGNT) has entered into an agreement to acquire the 50% interest of its joint venture partner, Chengdu Kanghong Pharmaceuticals (Group), formerly Chengdu Kanghong Technology (Group) in the Kanghong Sagent (Chengdu) Pharmaceutical (KSCP) joint venture, for $25 million, payable in installments through September 2015. On completion of the acquisition, which is expected in the next several months, KSCP will become a wholly-owned subsidiary of Sagent. 6 May 2013